Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
The Oncologist · 07.10.2026 · 31 (11)
DOI: 10.1093/oncolo/oyag413 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 19.10.2026. Verfasst von Jean-Louis Lacaze und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Receptors, Estrogen, Receptors, Progesterone. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2− OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients. Materials and Methods All consecutive patients with HR+/HER2− OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as ≤5 metastases. Prognostic factors, including biological subtype, anatomical distribution, imaging modality, and LAT, were evaluated for overall and progression-free survival (OS, PFS).
Results
Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR] = 0.52; 95% CI: 0.29-0.91, P = .0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR = 0.29; 95% CI: 0.12-0.73, P = .008) and PFS (HR = 0.40; 95% CI: 0.21-0.77, P = .0064). After first-line systemic therapy, only 18% developed polymetastatic progression.
Conclusion
In HR+/HER2− OMBC, 3 actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
- Biostatistics & Health Data Science Unit, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
- Department of Radiology, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
- Department of Radiotherapy, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
- Department of Surgery, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
ORCID-Profile: Jean-Louis Lacaze, Bastien Cabarrou, Thibaut Cassou-Mounat, Celine Dalmasso, Eleonora De Maio, Eva Jouve, Clément Korenbaum, Carole Massabeau, François Poumeaud, Gabrielle Selmes
Zitieren
APA
Lacaze, J. L., Cabarrou, B., Cassou-Mounat, T., Chira, C., Dalmasso, C., De Maio, E., Jouve, E., Korenbaum, C., Massabeau, C., Nicolai, V., Poumeaud, F., Selmes, G., & Ung, M. (2026). Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag413
Vancouver
Lacaze JL, Cabarrou B, Cassou-Mounat T, Chira C, Dalmasso C, De Maio E, et al. Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag413
BibTeX
@article{Lacaze2026,
author = {Lacaze, Jean-Louis and Cabarrou, Bastien and Cassou-Mounat, Thibaut and Chira, Ciprian and Dalmasso, Celine and De Maio, Eleonora and Jouve, Eva and Korenbaum, Clément and Massabeau, Carole and Nicolai, Vincent and Poumeaud, François and Selmes, Gabrielle and Ung, Mony},
title = {Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {11},
doi = {10.1093/oncolo/oyag413}
}
EUVIMED